Evaluation of Heart Failure Telemonitoring Eligibility Criteria
NCT ID: NCT07278583
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
130 participants
OBSERVATIONAL
2025-12-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort of Heart Failure Patients
NCT03422991
Clinical and Therapeutic Characteristics of Geriatric Patients Hospitalized for Heart Failure (AGING HF Study (AGe and Heart Failure IN Geriatrics))
NCT06377904
Heart Failure Educational and Follow up Platform
NCT02110433
Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation
NCT05097898
HeartLogic France Study: Heart Failure Patients Managed with the HeartLogic Algorithm
NCT04619888
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The inclusion criteria correspond to either an episode of heart failure in the last 12 months or dyspnea at least NYHA2 with NT-proBNP over 1000pg/mL.
The follow up is renewed every 6 months. Patients are excluded from monitoring when criteria are no longer fulfilled. As these characteristics have been chosen empirically, our aim is to see if patients no longer presenting these standards have indeed a low chance of bad evolution.
Information is gathered from their medical record at inclusion, exclusion and 1 year after exclusion. A short phone call is made after 1 year of exclusion, to appreciate their evolution and gather information concerning their symptoms, treatments ...
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to read and understand french
* included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg/mL) and excluded by medical decision as no longer presenting eligibillity criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clément RIOCREUX
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
Rapport au parlement "évaluation des expérimentations de télésurveillance du programme national étapes" Novembre 2020
Haute Autorité Santé. "Télésurveillance médicale du patient insuffisant cardiaque chronique," 2023.
Authors/Task Force Members:; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNI 2025 RIOCREUX
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.